YAP1 and cholangiocarcinoma: Therefore, we recruited TEAD reporter plasmids to confirm YAP1 activity and cytoplasmic/nucleus protein components to ensure that YAP1 translocation events occur in the regorafenib treatment model of CCA cells (Fig. 1E, F).